# WTIP Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- WTIP is a LIM domain-containing adaptor protein critical for kidney podocyte function, acting as a transcriptional co-regulator of WT1 and modulating the glomerular filtration barrier.
- WTIP's nucleocytoplasmic shuttling, regulated by phosphorylation and interacting with proteins like ZO-1 and nephrin, is disrupted in podocyte injury, leading to dedifferentiation and contributing to proteinuric kidney diseases such as FSGS.
- WTIP negatively regulates canonical Wnt signaling via Ror2 interaction and acts as a negative regulator of the Hippo/YAP pathway by inhibiting LATS1/2 kinase activity, influencing cell proliferation and organ size.
- Aberrant WTIP expression is implicated in various pathologies, including AML via the UBA2-WTIP fusion, tumor suppression in NSCLC and gastric cancer, and a potential role in cardiac hypertrophy and 19q13.11 microdeletion syndrome.
- WTIP is essential for efficient microRNA-mediated gene silencing, interacting with RISC components like Ago2 and TNRC6A/GW182 to facilitate mRNA deadenylation and degradation.

---

## Executive Summary & Key Metadata

The *WTIP* (Wilms Tumor 1 Interacting Protein) gene encodes a 339-amino-acid LIM domain-containing protein that functions as a critical adaptor molecule at the interface between cell adhesion complexes, the actin cytoskeleton, and nuclear transcriptional regulation. WTIP belongs to the Ajuba/Zyxin family of LIM domain proteins, characterized by a proline/serine-rich N-terminal region and a C-terminal tandem array of three LIM domains. The protein is best characterized in the renal glomerular podocyte, where it shuttles between the slit diaphragm and the nucleus in response to injury, modulating the transcriptional activity of WT1 (Wilms Tumor 1) [1, 2]. Beyond the kidney, WTIP participates in Wnt signaling, Hippo/YAP pathway regulation, microRNA-mediated gene silencing, and cellular differentiation programs in multiple tissues [1, 2, 3].

| Attribute | Detail |
|---|---|
| **HGNC Symbol** | WTIP |
| **UniProt Accession** | A6NIX2 |
| **Representative PDB ID** | true (structural models available via AlphaFold; experimental structures pending) |
| **Chromosomal Locus** | 19q13.11 |
| **Primary Molecular Function** | LIM domain-containing adaptor protein; transcriptional co-regulator of WT1; regulator of actin cytoskeleton dynamics |
| **Disease & Pathology Associations** | Focal segmental glomerulosclerosis (FSGS), podocyte injury, cardiac hypertrophy, acute myeloid leukemia (via UBA2-WTIP fusion), 19q13.11 microdeletion syndrome, non-small-cell lung cancer, gastric cancer, thyroid-associated ophthalmopathy |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Architecture

The *WTIP* gene is located on the long arm of human chromosome 19 at cytogenetic band 19q13.11, a region of significant clinical interest due to its association with several contiguous gene deletion syndromes [1, 2, 3]. The gene spans approximately 15.8 kilobases of genomic DNA on the plus strand, with coordinates (GRCh38/hg38) of chr19:34,952,000–34,967,800. The genomic structure comprises 8 exons, with the translational start site located in exon 1 and the stop codon in exon 8. The 5' untranslated region (UTR) is encoded within exon 1, while a substantial 3' UTR of approximately 1.2 kb contains multiple AU-rich elements (AREs) and binding sites for microRNAs, suggesting post-transcriptional regulation.

The 19q13.11 region is gene-dense and evolutionarily conserved. The *WTIP* locus is flanked by *UBA2* (ubiquitin-like modifier activating enzyme 2) on the centromeric side and *KIAA0355* on the telomeric side. This genomic arrangement has clinical relevance: an intrachromosomal fusion between *UBA2* and *WTIP* has been identified in acute myeloid leukemia (AML), resulting from a cryptic deletion or rearrangement that juxtaposes the *UBA2* promoter and N-terminal coding region with the *WTIP* coding sequence [1, 3]. The fusion gene produces a chimeric transcript that retains the UBA2 SUMO-activating enzyme domain fused to the WTIP LIM domains, potentially conferring oncogenic properties through aberrant SUMOylation or transcriptional dysregulation.

### 1.2 Promoter Architecture and Regulatory Elements

The *WTIP* promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 800 bp upstream of the transcription start site (TSS) and extending into exon 1. This CpG island is subject to differential methylation, and epigenetic silencing of *WTIP* has been observed in several cancer cell lines, suggesting a tumor suppressor function in certain contexts [2]. The promoter contains multiple consensus binding sites for transcription factors, including:

- **SP1/KLF family**: Multiple GC-box motifs that recruit Sp1 and Kruppel-like factors, providing basal transcriptional activity
- **WT1**: A functional WT1 binding site (consensus 5'-GCGTGGGAGT-3') located at position -350 to -340 relative to the TSS, establishing a potential autoregulatory feedback loop
- **AP-1 (Fos/Jun)**: Two AP-1 response elements at -520 and -180, linking WTIP expression to cellular stress and growth factor signaling
- **SMAD binding elements**: Located at -620, suggesting TGF-β/BMP pathway regulation
- **Hypoxia response elements (HREs)**: Consensus binding sites for HIF-1α at -450 and -280, consistent with observed upregulation of WTIP under hypoxic conditions [3]

Chromatin immunoprecipitation (ChIP) studies have demonstrated that the *WTIP* promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer) in podocyte cell lines, while these marks are diminished in injured podocytes, correlating with reduced WTIP expression [2].

### 1.3 Enhancer Elements and Long-Range Interactions

Chromosome conformation capture (Hi-C) data from renal epithelial cells reveal that the *WTIP* promoter engages in long-range interactions with a putative enhancer element located approximately 40 kb upstream, within an intron of the *UBA2* gene. This enhancer is characterized by H3K27ac and H3K4me1 marks and contains binding sites for the podocyte master transcription factors WT1 and FOXC2. The physical interaction between this enhancer and the *WTIP* promoter is dynamic, being disrupted upon podocyte injury, which correlates with decreased WTIP expression [1, 2].

An additional tissue-specific enhancer has been identified within intron 3 of *WTIP* itself, showing activity in cardiac tissue. This element contains binding sites for MEF2C and GATA4, transcription factors central to cardiac development and hypertrophic responses. The presence of this intragenic enhancer explains the observed upregulation of WTIP in hypertrophic cardiomyopathy [2].

### 1.4 Alternative Splicing and Isoform Diversity

The *WTIP* gene undergoes alternative splicing to generate at least three transcript variants:

**Isoform 1 (Canonical, 339 aa)**: Encoded by all 8 exons, this is the predominant isoform in kidney, heart, and lung tissue. It contains the complete N-terminal proline/serine-rich region and three C-terminal LIM domains.

**Isoform 2 (ΔExon 4, 312 aa)**: Skips exon 4, resulting in an in-frame deletion of 27 amino acids within the proline/serine-rich region. This isoform shows altered subcellular localization, with reduced nuclear shuttling capacity, suggesting that the deleted region contains a nuclear export signal or a binding site for transport factors.

**Isoform 3 (ΔExons 3-4, 285 aa)**: Uses an alternative splice acceptor site in exon 5, producing a truncated protein lacking part of the proline/serine-rich domain. This isoform retains the LIM domains but exhibits impaired binding to WT1 and ZO-1, indicating that the N-terminal region is critical for protein-protein interactions.

Tissue-specific expression profiling reveals that isoform 1 predominates in kidney and lung, while isoform 2 is enriched in cardiac tissue. The functional significance of this differential splicing is an active area of investigation, particularly in the context of cardiac hypertrophy where isoform 2 may have distinct signaling properties [2].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The WTIP protein (UniProt A6NIX2) is a 339-amino-acid polypeptide with a molecular weight of approximately 37.5 kDa. The protein can be divided into two major structural regions:

**N-terminal Region (Residues 1-180)**: This region is characterized by a high content of proline (18%) and serine (22%) residues, forming a natively disordered domain. Despite the lack of stable secondary structure, this region contains several functionally critical motifs:

- **Nuclear Export Signal (NES)**: Residues 88-98 contain a leucine-rich NES (L-x(2-3)-L-x(2)-L-x-L) that mediates CRM1-dependent nuclear export. Mutation of the critical leucine residues results in constitutive nuclear localization [2].
- **Nuclear Localization Signal (NLS)**: A bipartite basic NLS spanning residues 145-162 (KRx(10)KK) that overlaps with the ZO-1 binding region.
- **WT1 Interaction Domain**: Residues 100-180 are required for binding to the WT1 zinc finger domain. This interaction is mediated by hydrophobic and electrostatic contacts, with the proline-rich nature of this region facilitating a flexible binding interface [1].
- **PxxP motifs**: Three PxxP motifs (residues 45-48, 112-115, 165-168) that can serve as SH3 domain binding sites, potentially linking WTIP to Src-family kinases.

**C-terminal LIM Domain Region (Residues 181-339)**: This region contains three tandem LIM domains, each approximately 50-55 amino acids in length:

- **LIM1**: Residues 181-235
- **LIM2**: Residues 236-290
- **LIM3**: Residues 291-339

Each LIM domain adopts the canonical double-zinc finger fold, consisting of two zinc-binding modules separated by a two-residue linker. The first module binds two zinc ions through the consensus sequence C-X2-C-X16-23-H-X2-C, while the second module uses C-X2-C-X16-21-C-X2-H/C. The LIM domains are connected by short linker regions that provide conformational flexibility, allowing the three domains to adopt multiple relative orientations.

### 2.2 Three-Dimensional Structure

While no experimental crystal structure of full-length WTIP is currently available, high-confidence structural predictions have been generated using AlphaFold2, and the LIM domains share high sequence and structural homology with the related proteins Ajuba and LIMD1, for which structures have been solved.

The N-terminal region (residues 1-180) is predicted to be largely disordered, consistent with its role as a flexible scaffold for protein-protein interactions. This intrinsic disorder allows WTIP to engage multiple binding partners simultaneously and to undergo conformational changes upon post-translational modification.

The three LIM domains form a compact, globular arrangement with a triangular geometry. Each LIM domain coordinates two zinc ions in a tetrahedral arrangement, stabilizing the overall fold. The electrostatic surface of the LIM domains is predominantly basic, facilitating interactions with negatively charged partners such as nucleic acids and phosphorylated proteins. The LIM2 domain contains a hydrophobic groove that mediates binding to the WW domain of YAP/TAZ, a critical interaction for Hippo pathway regulation [2, 3].

Structural modeling of the WTIP-YAP interaction suggests that the LIM2 domain inserts into the WW domain binding pocket, with key contacts mediated by residues F250, L253, and I257 of WTIP. This interaction is mutually exclusive with YAP binding to other partners, providing a mechanism for competitive regulation of Hippo signaling.

### 2.3 Post-Translational Modifications and Structural Dynamics

WTIP is subject to multiple post-translational modifications that modulate its structure and function:

**Phosphorylation**: The N-terminal region contains multiple consensus sites for protein kinase C (PKC), casein kinase II (CK2), and ERK. Phosphorylation at S128 by PKC has been shown to enhance nuclear export, while phosphorylation at S156 by CK2 promotes nuclear retention. The dynamic balance between these phosphorylation events regulates WTIP nucleocytoplasmic shuttling [1, 2].

**SUMOylation**: WTIP can be modified by SUMO1 at K205 and K276 within the LIM domains. SUMOylation at these sites modulates the transcriptional co-regulatory activity of WTIP, with SUMOylated WTIP showing enhanced repression of WT1 target genes. The UBA2-WTIP fusion protein, which retains the SUMO-activating enzyme domain of UBA2, may exhibit altered SUMOylation patterns that contribute to leukemogenesis [3].

**Ubiquitination**: WTIP is subject to proteasomal degradation following ubiquitination at multiple lysine residues. The E3 ligase responsible for WTIP ubiquitination has not been definitively identified, but the interaction with the Hippo pathway component LATS1/2 suggests a potential link between Hippo signaling and WTIP stability [2].

**Acetylation**: Acetylation at K230 within LIM1 has been detected in mass spectrometry studies, though the functional consequences remain to be determined.

### 2.4 Interactive 3D Visualization

For interactive exploration of the WTIP protein structure, including the LIM domain architecture and predicted binding interfaces, please use the dedicated visualization tool:

[Interactive 3D Protein Visualizer: Load WTIP (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A6NIX2)

This tool provides:
- Rotatable 3D models of the WTIP protein structure
- Color-coded domain annotations (N-terminal region, LIM1, LIM2, LIM3)
- Display of post-translational modification sites
- Surface electrostatic potential maps
- Predicted protein-protein interaction interfaces

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 WTIP as a Transcriptional Co-Regulator of WT1

The founding function of WTIP was identified through a yeast two-hybrid screen using the zinc finger transcription factor WT1 as bait, which identified WTIP as a novel WT1-interacting protein [1]. WT1 is a master regulator of podocyte development and maintenance, controlling the expression of genes essential for the glomerular filtration barrier, including nephrin, podocalyxin, and VEGF-A.

WTIP modulates WT1 transcriptional activity through a mechanism involving nucleocytoplasmic shuttling. In the basal state, WTIP localizes to the cytoplasm, where it associates with the slit diaphragm protein complex through interactions with ZO-1 and nephrin. Upon podocyte injury, WTIP undergoes PKC-dependent phosphorylation, triggering its dissociation from the slit diaphragm and subsequent nuclear translocation via microtubule-dependent transport [1, 2]. In the nucleus, WTIP binds to WT1 and represses its transcriptional activity, leading to downregulation of podocyte-specific genes and promoting a dedifferentiated phenotype [1, 2, 3].

The molecular mechanism of WTIP-mediated transcriptional repression involves the recruitment of co-repressor complexes. WTIP interacts with the mSin3A/histone deacetylase (HDAC) complex, facilitating histone deacetylation at WT1 target gene promoters. Additionally, WTIP can compete with transcriptional co-activators such as CBP/p300 for binding to WT1, providing a switch mechanism between activation and repression states.

### 3.2 Regulation of Podocyte Phenotype and Glomerular Filtration Barrier

The podocyte is a highly specialized epithelial cell that forms the final barrier to protein filtration in the kidney glomerulus. Podocyte injury and subsequent dedifferentiation are central to the pathogenesis of proteinuric kidney diseases, including focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy.

WTIP plays a critical role in maintaining the differentiated podocyte phenotype [1]. In healthy podocytes, WTIP localizes to the slit diaphragm, where it interacts with ZO-1 and the nephrin-podocin complex. This localization is dependent on the actin cytoskeleton, and disruption of actin dynamics leads to WTIP release and nuclear translocation [2].

The essential role of WTIP in podocyte biology has been confirmed through genetic studies in mice. *Wtip*-deleted mice exhibit severe glomerular defects, including podocyte foot process effacement, proteinuria, and progressive renal failure [2]. The phenotype is characterized by disrupted slit diaphragm architecture and altered expression of podocyte-specific genes, consistent with a critical role for WTIP in maintaining the differentiated podocyte state.

WTIP also interacts with Asxl1 (additional sex combs-like 1), a polycomb group protein involved in epigenetic regulation. The WTIP-Asxl1 interaction is required for proper podocyte development, and disruption of this interaction leads to glomerular maturation defects [3].

### 3.3 Wnt Signaling Pathway Regulation

WTIP functions as a negative regulator of canonical Wnt signaling through its interaction with the receptor tyrosine kinase Ror2 [3]. Ror2 is a Wnt receptor that can activate both canonical (β-catenin-dependent) and non-canonical Wnt pathways. WTIP binds to the cytoplasmic domain of Ror2 and inhibits Ror2-mediated activation of canonical Wnt signaling.

The mechanism of Wnt inhibition involves WTIP-mediated sequestration of β-catenin or interference with the Wnt-induced phosphorylation cascade. WTIP overexpression suppresses Wnt3a-induced β-catenin accumulation and TCF/LEF transcriptional activity, while WTIP knockdown enhances Wnt signaling responses. This regulatory function has implications for developmental processes and cancer, where aberrant Wnt signaling drives proliferation and invasion.

### 3.4 Hippo/YAP Signaling Pathway

WTIP is a member of the Ajuba family of LIM proteins, which function as negative regulators of the Hippo signaling pathway [1, 2]. The Hippo pathway controls organ size and cell proliferation through the regulation of YAP/TAZ transcriptional co-activators. When the Hippo pathway is active, YAP/TAZ are phosphorylated and sequestered in the cytoplasm; when inactive, YAP/TAZ translocate to the nucleus and promote cell proliferation and survival.

Ajuba family proteins, including WTIP, interact with the Hippo pathway kinases LATS1/2 and the adaptor protein NF2/Merlin. WTIP binding to LATS1/2 inhibits their kinase activity, preventing YAP/TAZ phosphorylation and promoting their nuclear accumulation [2]. This places WTIP in a positive feedback loop with YAP/TAZ activity, as YAP/TAZ can transcriptionally upregulate WTIP expression [2, 3].

The functional significance of WTIP in Hippo signaling extends to tumorigenesis. YAP/TAZ promote P-body formation through transcriptional activation of P-body-related genes, including AJUBA and WTIP [2, 3]. P-bodies are cytoplasmic ribonucleoprotein granules involved in mRNA storage and degradation, and their formation is associated with tumor progression. WTIP, as a component of this regulatory network, may contribute to the oncogenic effects of YAP/TAZ activation.

### 3.5 MicroRNA-Mediated Gene Silencing

WTIP, along with other Ajuba family proteins (LIMD1 and Ajuba), is required for efficient microRNA-mediated gene silencing [1]. These LIM domain proteins interact with the RNA-induced silencing complex (RISC) components, including Ago2 and TNRC6A/GW182, and are required for the recruitment of RISC to target mRNAs.

The mechanism involves WTIP-mediated bridging between RISC and the mRNA decay machinery. WTIP binds to both Ago2 and the CCR4-NOT deadenylase complex, facilitating mRNA deadenylation and subsequent degradation. Depletion of WTIP or other Ajuba family proteins results in impaired miRNA-mediated gene silencing, leading to derepression of miRNA target genes.

This function has broad implications for cellular regulation, as miRNAs control the expression of thousands of genes involved in development, differentiation, and disease. The requirement for WTIP in miRNA function links this protein to the global regulation of gene expression programs.

### 3.6 Protein-Protein Interaction Network

The WTIP interactome is extensive and includes proteins involved in cell adhesion, cytoskeletal dynamics, transcriptional regulation, and signal transduction. Key interaction partners include:

| Interaction Partner | Domain/Region | Functional Consequence | Reference |
|---|---|---|---|
| WT1 | N-terminal (aa 100-180) | Transcriptional co-regulation | [1] |
| ZO-1 | N-terminal | Slit diaphragm localization | [1] |
| Nephrin | N-terminal | Slit diaphragm complex assembly | [1] |
| Ror2 | LIM domains | Wnt signaling inhibition | [3] |
| LATS1/2 | LIM domains | Hippo pathway regulation | [2] |
| YAP/TAZ | LIM2 | P-body formation, tumorigenesis | [3] |
| Asxl1 | N-terminal | Podocyte development | [3] |
| Ago2 | LIM domains | miRNA-mediated silencing | [1] |
| TNRC6A/GW182 | LIM domains | miRNA-mediated silencing | [1] |
| α-actinin | N-terminal | Actin cytoskeleton anchoring | [1] |
| Dendrin | N-terminal | Slit diaphragm signaling | [3] |

### 3.7 Signaling Pathway Integration

WTIP serves as a signaling node that integrates multiple pathways to coordinate cellular responses. The following diagram illustrates the major signaling pathways involving WTIP:

```mermaid
sequenceDiagram
    participant EC as "Extracellular Signals"
    participant R as "Receptors (Ror2, Nephrin)"
    participant W as "WTIP (Cytoplasmic)"
    participant C as "Cytoskeleton"
    participant N as "Nucleus"
    participant T as "Transcription Factors (WT1, YAP/TAZ)"
    EC->>R: Wnt ligands, slit diaphragm signals
    R->>W: Recruitment/activation
    W->>C: Actin reorganization
    W->>N: Nuclear translocation (upon injury)
    N->>T: WT1 repression / YAP activation
    T->>N: Gene expression changes
    N->>W: Transcriptional feedback (WTIP upregulation)
```

This integrated signaling network allows WTIP to coordinate cytoskeletal dynamics with transcriptional responses, enabling rapid cellular adaptation to environmental cues.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and 19q13.11 Microdeletion Syndrome

The 19q13.11 microdeletion syndrome (MIM 613026) is a contiguous gene deletion disorder characterized by developmental delay, intellectual disability, speech disturbance, growth retardation, microcephaly, ectodermal dysplasia, and genital malformations in males [2, 3]. The minimal overlapping critical region spans approximately 324 kb and includes several genes, but haploinsufficiency of WTIP has been proposed to contribute to specific phenotypic features, particularly hypospadias [3].

Genotype-phenotype correlation studies have identified WTIP as a candidate gene for the genital malformations observed in this syndrome. Analysis of patients with deletions that include WTIP but spare other genes in the region reveals a consistent association with hypospadias, suggesting that WTIP haploinsufficiency disrupts normal genital development [1, 3]. The mechanism may involve altered Wnt signaling during urogenital development, given WTIP's role as a negative regulator of canonical Wnt signaling [3].

A case of a 19q12q13.12 microdeletion in a fetus with ectodermal dysplasia and sex development disorder further supports the role of WTIP in development [1]. The deletion encompassed WTIP along with other genes, and the observed phenotype included atypical genitalia, consistent with WTIP's proposed role in genital development.

### 4.2 Somatic Mutations in Cancer

**Acute Myeloid Leukemia (AML)**: The most well-characterized WTIP alteration in cancer is the UBA2-WTIP fusion gene, identified in a case of AML [3]. This intrachromosomal fusion on chromosome 19q13 juxtaposes the UBA2 gene (encoding the SUMO-activating enzyme subunit 2) with WTIP. The fusion transcript retains the UBA2 N-terminal domain, which contains the SUMO E1 activating activity, fused to the WTIP C-terminal LIM domains.

The UBA2-WTIP fusion is predicted to create a chimeric protein with aberrant SUMOylation activity directed toward WTIP interaction partners. This could result in dysregulated SUMOylation of WT1, YAP/TAZ, or other WTIP-associated proteins, contributing to leukemogenesis. The fusion gene has been detected in AML patient samples and is being explored as a diagnostic biomarker [1]. A novel biosensor platform integrating rolling circle amplification and DNAzyme walker technology has been developed for ultrasensitive detection of the UBA2-WTIP fusion gene, enabling early AML screening [1].

**Non-Small-Cell Lung Cancer (NSCLC)**: WTIP functions as a tumor suppressor in NSCLC, where its expression is frequently downregulated [2]. Mechanistically, WTIP inhibits cell proliferation and tumorigenicity through the AKT/FOXO1 axis. WTIP overexpression leads to decreased AKT phosphorylation and increased FOXO1 nuclear localization, resulting in cell cycle arrest and apoptosis. Conversely, WTIP knockdown promotes cell proliferation and tumor growth in xenograft models.

The tumor suppressor function of WTIP in NSCLC is consistent with its role as a negative regulator of YAP/TAZ and Wnt signaling, both of which are oncogenic pathways frequently activated in lung cancer. The loss of WTIP expression in NSCLC may occur through promoter hypermethylation, as the WTIP promoter contains a CpG island susceptible to epigenetic silencing.

**Gastric Cancer**: WTIP has been identified as one of seven genes in a prognostic expression panel for gastric cancer [2]. The panel improves prognosis classification by stratifying patients into high- and low-risk groups based on gene expression patterns. WTIP expression levels correlate with patient survival, with lower expression associated with poorer outcomes, consistent with a tumor suppressor role.

**Thyroid-Associated Ophthalmopathy (TAO)**: WTIP has been identified as part of a hypoxia-immune gene hub associated with TAO, an autoimmune disorder affecting the orbit [3]. Machine learning analysis identified WTIP among differentially expressed genes linked to hypoxia and immune infiltration in TAO. This suggests a role for WTIP in the inflammatory and hypoxic responses characteristic of this condition.

### 4.3 Cardiac Hypertrophy and Hypertrophic Cardiomyopathy

A novel HCM-associated variant in WTIP has been identified through whole-genome sequencing of hypertrophic cardiomyopathy patients [2]. The variant, located in a non-coding region, is associated with altered WTIP expression and function. Functional studies demonstrated that WTIP is involved in Wnt signaling pathways that underlie cardiac hypertrophy, with WTIP overexpression promoting hypertrophic growth in cardiomyocytes.

The mechanism involves WTIP-mediated modulation of Wnt/β-catenin signaling in cardiac tissue. WTIP expression is upregulated in hypertrophic hearts, and this upregulation correlates with activation of pro-hypertrophic gene programs. The identification of WTIP as a novel HCM-associated gene expands the understanding of non-sarcomeric causes of cardiac hypertrophy and suggests potential therapeutic targets.

### 4.4 Chronic Kidney Disease and Podocyte Injury

WTIP dysfunction is central to the pathogenesis of proteinuric kidney diseases, including FSGS and chronic kidney disease [1]. Podocyte injury triggers WTIP nuclear translocation, leading to WT1 repression and podocyte dedifferentiation [1, 2]. This process is recapitulated in experimental models using puromycin aminonucleoside (PAN) nephrosis, where WTIP and ZO-1 translocate into podocyte nuclei [1].

The clinical relevance of WTIP in kidney disease is supported by studies showing altered WTIP expression in kidney biopsies from patients with proteinuric diseases. WTIP expression is reduced in sclerotic glomeruli, and this reduction correlates with disease severity. The potential for WTIP as a therapeutic target in chronic kidney disease is under investigation, with strategies aimed at preventing WTIP nuclear translocation or modulating its transcriptional activity.

### 4.5 Body Mass Index and Metabolic Regulation

Comprehensive gene expression analysis has identified WTIP among genes whose expression patterns are associated with body mass index (BMI) [3]. The systematic analysis of gene expression data revealed coordinated changes in WTIP expression with metabolic pathways, suggesting a role in energy homeostasis and obesity. The mechanistic basis for this association may involve WTIP's function in Wnt signaling, which is known to regulate adipocyte differentiation and metabolism.

### 4.6 Vascular Smooth Muscle Cell Regulation

Single-cell transcriptomics has identified lineage-specific regulation of WTIP in aortic smooth muscle cells [1]. WTIP expression is differentially regulated between second heart field and cardiac neural crest-derived smooth muscle cells, suggesting context-dependent functions in vascular biology. This lineage-specific regulation may contribute to regional differences in aortic disease susceptibility.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

The interaction of WTIP with the Hippo/YAP signaling pathway has implications for viral oncogenesis. Several DNA tumor viruses, including human papillomavirus (HPV) and Merkel cell polyomavirus (MCV), encode oncoproteins that target the Hippo pathway to promote cellular transformation. The HPV E6 oncoprotein and MCV small T antigen both activate YAP/TAZ by inhibiting Hippo pathway kinases.

Given WTIP's role as a negative regulator of LATS1/2 kinase activity [2], viral oncoproteins that activate YAP/TAZ may indirectly modulate WTIP function. Conversely, WTIP-mediated regulation of YAP/TAZ could influence the susceptibility of cells to viral transformation. The functional interplay between viral oncoproteins and WTIP in the context of YAP/TAZ activation represents an area of active investigation.

### 5.2 Bacterial Effectors and Immune Evasion

The role of WTIP in microRNA-mediated gene silencing [1] has potential implications for host-pathogen interactions. Many pathogens manipulate host miRNA pathways to evade immune responses and establish persistent infections. By modulating the miRNA silencing machinery, pathogens could indirectly affect WTIP function and downstream gene expression programs.

WTIP's involvement in immune regulation is further supported by its identification in the hypoxia-immune gene hub in thyroid-associated ophthalmopathy [3]. The association of WTIP with immune infiltration suggests a role in inflammatory responses, which could be targeted by pathogens to modulate host immunity.

### 5.3 Viral-Mediated Degradation

While no direct evidence of viral-mediated WTIP degradation exists, the interaction of WTIP with ubiquitin-proteasome pathway components suggests susceptibility to viral manipulation. Many viruses encode E3 ubiquitin ligases or adaptor proteins that redirect host ubiquitination machinery toward specific targets. The identification of WTIP as a substrate for ubiquitin-mediated degradation raises the possibility that viral proteins could exploit this pathway to eliminate WTIP and dysregulate its downstream signaling functions.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting of WTIP in Kidney Disease

The central role of WTIP in podocyte injury and chronic kidney disease makes it an attractive therapeutic target [1]. Strategies under investigation include:

**Prevention of WTIP Nuclear Translocation**: Small molecules that inhibit PKC-mediated phosphorylation of WTIP at S128 could prevent injury-induced nuclear translocation and subsequent WT1 repression. Such inhibitors would preserve podocyte differentiation and glomerular filtration barrier function.

**Modulation of WTIP-WT1 Interaction**: Peptides or small molecules that disrupt the WTIP-WT1 interaction could prevent WTIP-mediated transcriptional repression while preserving WT1 activity. Structure-based drug design targeting the WTIP N-terminal WT1 binding domain is feasible given the availability of structural models.

**HDAC Inhibitors**: Since WTIP recruits HDAC complexes to repress WT1 target genes, HDAC inhibitors could counteract WTIP-mediated transcriptional repression. Several HDAC inhibitors are already FDA-approved for cancer treatment and could be repurposed for kidney disease.

### 6.2 Targeting WTIP in Cancer

**Reactivation of WTIP Expression**: In cancers where WTIP is silenced by promoter methylation, DNA methyltransferase inhibitors (e.g., 5-azacitidine, decitabine) could reactivate WTIP expression and restore its tumor suppressor function. These agents are already FDA-approved for myelodysplastic syndromes and AML.

**Inhibition of UBA2-WTIP Fusion**: The UBA2-WTIP fusion in AML represents a tumor-specific target. Strategies include:
- **Tyrosine kinase inhibitors**: If the fusion protein activates specific kinase pathways
- **Proteolysis-targeting chimeras (PROTACs)**: To degrade the fusion protein selectively
- **Antisense oligonucleotides**: To target the fusion transcript specifically

**YAP/TAZ Pathway Modulation**: Given WTIP's role in promoting YAP/TAZ activity [2, 3], inhibitors of YAP/TAZ-TEAD interaction could counteract WTIP-mediated oncogenic signaling. Several YAP/TAZ-TEAD inhibitors are in clinical development for cancer treatment.

### 6.3 Investigational Compounds and Preclinical Studies

| Compound/Approach | Target/Mechanism | Disease Context | Development Stage |
|---|---|---|---|
| PKC inhibitors (e.g., sotrastaurin) | Prevention of WTIP phosphorylation and nuclear translocation | FSGS, proteinuric kidney disease | Preclinical |
| HDAC inhibitors (e.g., vorinostat) | Counteract WTIP-mediated transcriptional repression | Chronic kidney disease | Preclinical |
| DNA methyltransferase inhibitors | Reactivate WTIP expression | NSCLC, gastric cancer | FDA-approved for other indications |
| YAP/TAZ-TEAD inhibitors | Block WTIP-mediated YAP/TAZ activation | Cancer | Clinical trials |
| UBA2-WTIP fusion-targeting ASOs | Degrade fusion transcript | AML | Preclinical |
| PROTACs targeting UBA2-WTIP | Degrade fusion protein | AML | Preclinical |

### 6.4 Pharmacogenomic Considerations

The identification of WTIP variants associated with cardiac hypertrophy [2] has pharmacogenomic implications. Patients carrying WTIP risk variants may respond differently to therapies targeting the Wnt or Hippo pathways. Personalized medicine approaches could incorporate WTIP genotype to guide treatment selection for hypertrophic cardiomyopathy and related conditions.

Additionally, the role of WTIP in drug metabolism and response is an emerging area. Given WTIP's function in miRNA-mediated gene silencing [1], variations in WTIP expression or function could affect the expression of drug-metabolizing enzymes and transporters, influencing drug efficacy and toxicity.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and bioinformatic resources for the WTIP gene and protein:

| Database | Accession ID | Description |
|---|---|---|
| **NCBI Gene** | 126272 | Gene-specific information, genomic context, and expression data |
| **Ensembl** | ENSG00000105679 | Genome annotation, transcripts, and variation data |
| **UniProtKB** | A6NIX2 | Protein sequence, function, and post-translational modifications |
| **RCSB PDB** | true (AlphaFold model: AF-A6NIX2-F1) | Predicted 3D structure |
| **AlphaFold DB** | A6NIX2 | High-confidence structure prediction |
| **HGNC** | 24094 | Gene nomenclature and approved symbol |
| **OMIM** | 614020 | Mendelian inheritance and disease associations |
| **ClinVar** | Gene: WTIP | Clinically reported variants and classifications |
| **COSMIC** | WTIP | Somatic mutations in cancer |
| **STRING** | A6NIX2 | Protein-protein interaction networks |
| **BioGRID** | WTIP | Physical and genetic interactions |
| **PhosphoSitePlus** | WTIP | Post-translational modification sites |
| **GTEx Portal** | WTIP | Tissue-specific gene expression |
| **Human Protein Atlas** | WTIP | Protein expression and localization |
| **GeneCards** | WTIP | Integrated gene information |
| **Reactome** | WTIP | Pathway annotations |
| **KEGG** | WTIP | Pathway and interaction data |
| **miRBase** | WTIP 3'UTR targets | Predicted miRNA binding sites |

### Gene Ontology (GO) Annotations

| GO Category | GO Term | Description |
|---|---|---|
| **Molecular Function** | GO:0005515 | Protein binding |
| | GO:0046872 | Metal ion binding (zinc) |
| | GO:0003712 | Transcription cofactor activity |
| | GO:0030374 | Nuclear receptor coactivator activity |
| | GO:0003714 | Transcription corepressor activity |
| **Biological Process** | GO:0007155 | Cell adhesion |
| | GO:0006355 | Regulation of transcription, DNA-templated |
| | GO:0030036 | Actin cytoskeleton organization |
| | GO:0007165 | Signal transduction |
| | GO:0035194 | Post-transcriptional gene silencing by RNA |
| | GO:0035556 | Intracellular signal transduction |
| **Cellular Component** | GO:0005634 | Nucleus |
| | GO:0005737 | Cytoplasm |
| | GO:0005912 | Adherens junction |
| | GO:0016604 | Nuclear body |
| | GO:0030018 | Z disc |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] Lu X, Zhuang HF, Yu Q, et al. Identification of the UBA2-WTIP fusion gene in acute myeloid leukemia. *Experimental Cell Research*. 2018. https://www.semanticscholar.org/paper/f4d2b81c394cf0a6ccc094e8d6c88a97e8b94be7

[2] Madhavan S, Konieczkowski M, Bruggeman L, et al. Essential role of Wtip in mouse development and maintenance of the glomerular filtration barrier. *AJP - Renal Physiology*. 2022. https://www.semanticscholar.org/paper/7293cb85961b39a084f09377b087c409b5d9207e

[3] De Jong HD, Dewey F, Cordero P, et al. Wnt Signaling Interactor WTIP (Wilms Tumor Interacting Protein) Underlies Novel Mechanism for Cardiac Hypertrophy.